



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Term Extension Application
Filed : March 6, 1997
For : USPN 5,171,569; Issued: December 15, 1992
For : FACTOR IX PREPARATIONS UNCONTAMINATED BY
PLASMA COMPONENTS OR POX VIRUS

GP 7814
1652
7/764073

MAR 12 1999
4300
GROUP 18
#44
8-7-00
19

March 3, 1999

VIA FACSIMILE

(703) 308-6916

ATTN: Hiram H. Bernstein

Senior Legal Advisor

Special Program Law Office

Office of the Deputy Assistant Commissioner

for Patent Policy and Projects

Assistant Secretary and Honorable

Commissioner of Patents and Trademarks

Box Patent Ext.

Washington, DC 20231

Certificate of Facsimile Transmission	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Steven R. Lazar	
Type or print name of person signing certificate.	
Signature	Date
	3/3/99

STATUS INQUIRY

We are in receipt of a letter, dated July 24, 1998, from the United States Food and Drug Administration to the United States Patent and Trademark Office, which advises that the FDA has determined that BeneFIX [recombinant human Factor IX protein] is a product which was subject to a regulatory review period, and is therefore eligible for patent term extension. However, we have not seen publication of a notice in the Federal Register of such determination, nor have we received any further communication from either the FDA or the PTO.

The Applicants respectfully request information regarding the status of the present application for patent term extension. The Advisor is invited to contact the attorney listed below.

Respectfully submitted,

Steven R. Lazar
Reg. No. 32,618
Attorney for Applicants
(617) 498-8260

Genetics Institute, Inc.
87 CambridgePark Drive
Cambridge, MA 02140